背景:肌少症与慢性阻塞性肺疾病(COPD)之间的关系已被越来越多的报道,它们的临床特征和肺康复(PR)策略有一些重叠。没有韩国研究报告建议进行肺康复的稳定COPD患者中肌肉减少症的实际患病率。本研究评估了老年门诊稳定期COPD患者肌肉减少症的患病率和临床特征以及6个月后的变化。
方法:在这项横断面和6个月的随访研究中,我们招募了63名年龄≥65岁的确诊为稳定期COPD的男性.使用AWGS2019标准诊断肌肉减少症,其中包括手握力测试,生物电阻抗分析,短物理性能电池管理,和力量,帮助散步,从椅子上升起,爬楼梯,和下降筛查工具管理。进行了6分钟步行测试(6MWT),强迫肺活量(FVC),1s用力呼气容积(FEV1),最大吸气和呼气压力(MIP和MEP,分别)和峰值呼气流量(PEF)进行评估,并进行患者报告问卷。
结果:在基线时,14例(22%)患者被诊断为可能的肌少症,8人(12.6%)被诊断为肌肉减少症。在年龄、体重指数、体重指数、气流阻塞,呼吸困难,和运动指数;改良医学研究理事会呼吸困难评分;以及正常组和肌肉减少组之间的国际身体活动问卷评分。全身相位角,MIP,MEP,PEF,6分钟步行距离(6MWD)也显示出显着差异。超过6个月,FEV1降低的患者比例增加;然而,肌肉减少症患者的比例没有增加.
结论:在患有稳定期COPD的老年门诊患者中观察到肌肉减少症的患病率相对较低。在6个月的随访期内,肌少症的患病率没有显着变化。
背景:该研究已在临床研究信息服务(KCT0006720)注册。注册日期:2021年7月30日。
BACKGROUND: The relationship between sarcopenia and chronic obstructive pulmonary disease (COPD) has been increasingly reported, and there is some overlap regarding their clinical features and pulmonary rehabilitation (PR) strategies. No Korean study has reported the actual prevalence of sarcopenia in patients with stable COPD who are recommended for pulmonary rehabilitation. This study evaluated the prevalence and clinical features of sarcopenia in older adult outpatients with stable COPD and the changes after 6 months.
METHODS: In this cross-sectional and 6-month follow-up study, we recruited 63 males aged ≥ 65 diagnosed with stable COPD. Sarcopenia was diagnosed using the AWGS 2019 criteria, which included hand grip strength testing, bioelectrical impedance analysis, Short Physical Performance Battery administration, and Strength, Assistance with walking, Rising from a chair, Climbing stairs, and Falling screening tool administration. A 6-minute walk test (6 MWT) was conducted, forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), maximal inspiratory and expiratory pressures (MIP and MEP, respectively) and peak expiratory flow (PEF) were assessed, and patient-reported questionnaires were administered.
RESULTS: At baseline, 14 (22%) patients were diagnosed with possible sarcopenia, and eight (12.6%) were diagnosed with sarcopenia. There were significant differences in the age; body mass index; Body mass index, airflow Obstruction, Dyspnea, and Exercise index; modified Medical Research Council dyspnea scores; and International Physical Activity Questionnaire scores between the normal and sarcopenia groups. Whole-body phase angle, MIP, MEP, PEF, and 6-minute walk distance (6 MWD) also showed significant differences. Over 6 months, the proportion of patients with a reduced FEV1 increased; however, the proportion of patients with sarcopenia did not increase.
CONCLUSIONS: A relatively low prevalence of sarcopenia was observed in older adult outpatients with stable COPD. No significant change in the prevalence of sarcopenia was found during the 6-month follow-up period.
BACKGROUND: The study was registered with the Clinical Research Information Service (KCT0006720). Registration date: 30/07/2021.